Giacomo Chiesi Form 3 Kezar Life Sciences / Giacomo Chiesi ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Chiesi Ventures, Inc.

(Last) (First) (Middle)

P.O. BOX 110287

(Street)

RESEARCH TRIANGLE PARK NC 110287

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/20/2018

3. Issuer Name and Ticker or Trading Symbol
Kezar Life Sciences, Inc. [ KZR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B Preferred Stock, par value $0.001 per share	06/26/2017	(1)	Common Stock, par value $0.001 per share	314,819	(1)	I(2)	See footnote(2)

1. Name and Address of Reporting Person^*

Chiesi Ventures, Inc.

(Last) (First) (Middle)

P.O. BOX 110287

(Street)

RESEARCH TRIANGLE PARK NC 110287

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Chiesi Giacomo

(Last) (First) (Middle)

P.O. BOX 110287

(Street)

RESEARCH TRIANGLE PARK NC 110287

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Chiesi Ventures, LP

(Last) (First) (Middle)

P.O. BOX 110287

(Street)

RESEARCH TRIANGLE PARK NC 110287

(City) (State) (Zip)

Explanation of Responses:

1. The Series B Preferred Stock, par value $0.001 per share (the "Series B Stock") is convertible into Common Stock, $0.001 par value per share (the "Common Stock") of Kezar Life Sciences, Inc. (the "Company") on a one-for-one basis and has no expiration date. The number of underlying shares of common stock reported in Column 3 reflects a 1-for-5.62 reverse stock split that was effected by the Company on June 8, 2018.

2. These shares are held of record by Chiesi Ventures, LP ("Chiesi Ventures"). Chiesi Ventures, Inc. ("Chiesi") is the general partner of Chiesi Ventures, and Mr. Giacomo Chiesi is President of, and may be deemed to have control of, Chiesi. By virtue of their respectively relationships with Chiesi Ventures, each of Chiesi and Mr. Chiesi may be deemed to indirectly beneficially own the shares of which Chiesi Ventures is the record owner. Each of Chiesi and Mr. Chiesi disclaims beneficial ownership of the shares reported herein, except to the extent of its or his respective pecuniary interests therein. This report shall not be deemed an admission that such reporting persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Amanda Keister, attorney-in-fact for Chiesi Ventures, LP	06/20/2018
	/s/ Amanda Keister, attorney-in-fact for Chiesi Ventures, Inc.	06/20/2018
	/s/ Amanda Keister, attorney-in-fact for Giacomo Chiesi	06/20/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.